(Q45289817)

English

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.

scientific article published in March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

T Vassiliadis

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

N Nikolaidis

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

O Giouleme

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

K Tziomalos

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

N Grammatikos

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

K Patsiaoura

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

D Gkisakis

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

K Theodoropoulos

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

P Katsinelos

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

E Orfanou-Koumerkeridou

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

N Eugenidis

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

531-537

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

A novel selective broad-spectrum anti-DNA virus agent

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45289817&oldid=1584895236"